ICIs have transformed the paradigm of treatment for advanced NSCLC without EGFR, ALK, or ROS1 aberrations [12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.